SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who wrote (238)1/29/1998 8:06:00 AM
From: Henry Niman  Read Replies (2) of 4474
 
Martin, The first 4 paragraphs are on ARIA. First paragraph was on delivery of precise drug amounts in vivo. Second paragraph indicates that ARGENT expected to enter clinic next year. Initial focus on growth hormone, erythropoetin, alpha interferon. ARIA says therapeutic proteins represent $11 Billion in annual sales. Third paragraph defines technology (uses transcription factors). Fourth mentions additional platforms (functional genomics, small molecule drug design, regulated gene therapy).
I have linked the table of contents, as well as text of report on LGND, to home.att.net
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News